StreetInsider.com News Articles

Form 8-K TScan Therapeutics, Inc. For: Sep 08

Fri, 11 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27050862.html

H.C. Wainwright Downgrades Tscan Therapeutics Inc (TCRX) to Neutral

Tue, 08 Sep 2026 08:37:26 -0400

(Updated - September 8, 2026 8:37 AM EDT)

H.C. Wainwright analyst Andrew S. Fein downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Buy to Neutral with a price target of $1.00 (from $7.00).

The analyst comments "What’s new? Yesterday, TScan announced a company restructuring to focus on advancing its in vivo TCR-T program in solid tumors while pausing the heme program. Management plans to move its first two candidates targeting PRAME and MAGE-A4 into IND-enabling studies, with preclinical data expected in 1Q27 followed by an IND filing in 3Q27. As part of the company reorganization, TScan reduced its workforce by 75%, eliminated its

H.C. Wainwright Downgrades Tscan Therapeutics Inc (TCRX) to Neutral

Tue, 08 Sep 2026 08:37:26 -0400

(Updated - September 8, 2026 8:37 AM EDT)

H.C. Wainwright analyst Andrew S. Fein downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Buy to Neutral with a price target of $1.00 (from $7.00).

Needham Downgrades Tscan Therapeutics Inc (TCRX) to Hold

Wed, 02 Sep 2026 13:49:03 -0400

Needham analyst Gil Blum downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Buy to Hold.

For an analyst ratings summary and ratings history on Tscan Therapeutics Inc click here. For more ratings news on Tscan Therapeutics Inc click here.

Shares of Tscan Therapeutics Inc closed at $0.67 yesterday.

Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral

Wed, 02 Sep 2026 10:18:18 -0400

(Updated - September 2, 2026 10:18 AM EDT)

Wedbush analyst David Nierengarten downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Outperform to Neutral, PT $1.00 (from $5.00).

The analyst comments "We are downgrading TCRX to NEUTRAL and lowering our PT to $1 (from $5) following this morning’s strategic reorganization, which pauses further enrollment in the Ph 3 ALLOHA-2 study of TSC-101 despite positive early clinical data and redirects essentially all efforts toward two preclinical in vivo-engineered TCR-T programs targeting PRAME and MAGE-A4. As part of the restructuring, TCRX is reducing headcount by ~75% and eliminating internal manufacturing, extending runway into 4Q27. While TSC-101

Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral

Wed, 02 Sep 2026 10:18:18 -0400

(Updated - September 2, 2026 10:18 AM EDT)

Wedbush analyst David Nierengarten downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Outperform to Neutral, PT $1.00 (from $5.00).

Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral

Wed, 02 Sep 2026 10:18:18 -0400

(Updated - September 2, 2026 10:18 AM EDT)

Wedbush analyst David Nierengarten downgraded Tscan Therapeutics Inc (NASDAQ: TCRX) from Outperform to Neutral, PT $1.00 (from $5.00).

TScan cuts 75% of workforce, pivots to solid tumor cell therapy

Wed, 02 Sep 2026 07:01:16 -0400

TScan Therapeutics (Nasdaq: TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75%, shifting the company's focus to an in vivo-engineered T cell receptor (TCR-T) program targeting solid tumors.

The Waltham, Mass.-based company is advancing two product candidates — one targeting PRAME and one targeting MAGE-A4 — into IND-enabling studies. TScan plans to share preclinical data in Q1 2027, file its first investigational new drug (IND) application in Q3 2027, and initiate Phase 1 development in Q4 2027.

The reorganization is expected to generate cumulative cost savings of $55 million through the end of 2027. The company said its

TScan cuts 75% of workforce, pivots to solid tumor cell therapy

Wed, 02 Sep 2026 07:01:16 -0400

The reorganization is expected to generate cumulative cost savings of $55 million through the end of 2027. The company said its

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Wed, 02 Sep 2026 07:00:00 -0400

Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027

Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism

Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners

Workforce reduction of approximately 75% and strategic reorganization focuses resources on solid tumors and extends runway into Q4 2027

Company to host webcast

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Wed, 02 Sep 2026 07:00:00 -0400

Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027

Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism

Pauses further enrollment in Phase 3 ALLOHA-2™ study of TSC-101 due to insufficient capital; allowing data to mature and actively seeking collaboration partners

Workforce reduction of approximately 75% and strategic reorganization focuses resources on solid tumors and extends runway into Q4 2027

Company to host webcast

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Tue, 18 Aug 2026 17:00:00 -0400
si-local-file:///var/storage/secattach/20260818/26945226.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Tue, 18 Aug 2026 17:00:00 -0400
si-local-file:///var/storage/secattach/20260818/26945226.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260814/26931900.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260814/26931900.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 14 Aug 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260814/26931245.html

Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P

Fri, 14 Aug 2026 16:28:00 -0400
si-local-file:///var/storage/secattach/20260814/26931245.html

H.C. Wainwright Reiterates Buy Rating on Tscan Therapeutics Inc (TCRX)

Thu, 13 Aug 2026 07:00:07 -0400

H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $7.00 price target on Tscan Therapeutics Inc (NASDAQ: TCRX).
The analyst commented: "With promising initial data from Cohort C in hand, TScan heads into the Phase 3 ALLOHA-2 study with a validated, commercial ready manufacturing process. Of the 14 evaluable patients in the Phase 1 Cohort C ALLOHA-1 study, 13 (93%) responded with declining recipient chimerism and 11 (79%) achieved complete donor chimerism within 3 weeks of their first TSC-101 infusion, with 2 of the 3 remaining patients approaching complete donor chimerism by data cut off. These results were generated

TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 3c

Wed, 12 Aug 2026 07:43:39 -0400

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $1.88 million.
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

Form 10-Q TScan Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260812/26908946.html

Form 10-Q TScan Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400
si-local-file:///var/storage/secattach/20260812/26908946.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:15:00 -0400
si-local-file:///var/storage/secattach/20260812/26908850.html

Form 8-K TScan Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 07:15:00 -0400
si-local-file:///var/storage/secattach/20260812/26908850.html

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:00:00 -0400

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process

Cash and cash equivalents fund operations into the second quarter of 2027

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 07:00:00 -0400

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028

Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process

Cash and cash equivalents fund operations into the second quarter of 2027

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and